John Hunter Peel Alexander, MD

Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 2400 Pratt St, Durham, NC 27705
Phone (919) 668-8955
Email address john.h.alexander@duke.edu

John H. Alexander, MD, MHS is a cardiologist and Professor of Medicine in the Department of Medicine, Division of Cardiology at Duke University School of Medicine, as well as the Vice Chief, Clinical Research in the Division of Cardiology. He is the Director of Cardiovascular Research at the Duke Clinical Research Institute where he oversees a large group of clinical research faculty and a broad portfolio of cardiovascular clinical trials and observational clinical research programs. He is a member of the American Society of Clinical Investigation.

Dr. Alexander’s clinical interests are in acute and general cardiovascular disease, valvular heart disease, and echocardiology. His research is focused on the translation of novel therapeutic concepts into clinical data through clinical trials, specifically on the therapeutics of acute coronary syndromes, chronic coronary artery disease, and cardiac surgery and on novel methodological approaches to clinical trials. He was on the Executive Committee of the ARISTOTLE trial of apixaban in patients with atrial fibrillation and was the Principal Investigator of the APPRAISE-2 trial of apixaban in patients with acute coronary syndromes.

Dr. Alexander has published extensively and has served as the principal investigator of numerous multicenter clinical trials. He currently serves as the co-chair of the Clinical Trial Transformation Initiative (CTTI).

Education and Training

  • Fellow in Cardiology, Medicine, Duke University, 1996 - 2000
  • Medical Resident, Medicine, Children's Hospital Boston, 1993 - 1996
  • M.D., University of Pennsylvania, 1993

Publications

Vinereanu, D, Wang, A, Mulder, H, Lopes, RD, Jansky, P, Lewis, BS, Gersh, BJ, Avezum, A, Hanna, M, Held, C, Wallentin, L, Granger, CB, and Alexander, JH. "Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease." Heart (British Cardiac Society) 104, no. 15 (August 2018): 1292-1299.

PMID
29352007
Full Text

Horowitz, JD, De Caterina, R, Heresztyn, T, Alexander, JH, Andersson, U, Lopes, RD, Steg, PG, Hylek, EM, Mohan, P, Hanna, M, Jansky, P, Granger, CB, Wallentin, L, and ARISTOTLE Investigators, . "Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy." Journal of the American College of Cardiology 72, no. 7 (August 2018): 721-733.

PMID
30092948
Full Text

Inohara, T, Pieper, K, Wojdyla, DM, Patel, MR, Jones, WS, Tricoci, P, Mahaffey, KW, James, SK, Alexander, JH, Lopes, RD, Wallentin, L, Ohman, EM, Roe, MT, and Vemulapalli, S. "Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome." American Heart Journal 201 (July 2018): 25-32.

PMID
29910052
Full Text

Sharma, A, Hijazi, Z, Andersson, U, Al-Khatib, SM, Lopes, RD, Alexander, JH, Held, C, Hylek, EM, Leonardi, S, Hanna, M, Ezekowitz, JA, Siegbahn, A, Granger, CB, and Wallentin, L. "The Use of Biomarkers to Predict Specific Causes of Death in Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial." Circulation (June 5, 2018).

PMID
29871978
Full Text

Lopes, RD, Vora, AN, Liaw, D, Granger, CB, Darius, H, Goodman, SG, Mehran, R, Windecker, S, and Alexander, JH. "An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial." American Heart Journal 200 (June 2018): 17-23.

PMID
29898844
Full Text

Carson, JL, Stanworth, SJ, Alexander, JH, Roubinian, N, Fergusson, DA, Triulzi, DJ, Goodman, SG, Rao, SV, Doree, C, and Hebert, PC. "Clinical trials evaluating red blood cell transfusion thresholds: An updated systematic review and with additional focus on patients with cardiovascular disease." American Heart Journal 200 (June 2018): 96-101.

PMID
29898855
Full Text

Samad, Z, Shaw, LK, Phelan, M, Glower, DD, Ersboll, M, Toptine, JH, Alexander, JH, Kisslo, JA, Wang, A, Mark, DB, and Velazquez, EJ. "Long-term outcomes of mitral regurgitation by type and severity." American Heart Journal 203 (May 18, 2018): 39-48.

PMID
30015067
Full Text

Gurbel, PA, Tantry, US, D'Andrea, D, Chung, T, Alexander, JH, Bliden, KP, Wright, SD, and Tricoci, P. "Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study." Journal of Thrombosis and Thrombolysis 45, no. 4 (May 2018): 469-476.

PMID
29582212
Full Text

Wang, A, Wu, A, Wojdyla, D, Lopes, RD, Newby, LK, Newman, MF, Smith, PK, and Alexander, JH. "Dual antiplatelet therapy for perioperative myocardial infarction following CABG surgery." American Heart Journal 199 (May 2018): 150-155.

PMID
29754654
Full Text

Fanaroff, AC, Steffel, J, Alexander, JH, Lip, GYH, Califf, RM, and Lopes, RD. "Stroke prevention in atrial fibrillation: re-defining 'real-world data' within the broader data universe." European Heart Journal (April 23, 2018).

PMID
29688403
Full Text

Pages